<SEC-DOCUMENT>0001640334-23-000800.txt : 20230510
<SEC-HEADER>0001640334-23-000800.hdr.sgml : 20230510
<ACCEPTANCE-DATETIME>20230510171645
ACCESSION NUMBER:		0001640334-23-000800
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20230508
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230510
DATE AS OF CHANGE:		20230510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lexaria Bioscience Corp.
		CENTRAL INDEX KEY:			0001348362
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				202000871
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39874
		FILM NUMBER:		23907709

	BUSINESS ADDRESS:	
		STREET 1:		100 - 740 MCCURDY ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 2P7
		BUSINESS PHONE:		250-765-6424

	MAIL ADDRESS:	
		STREET 1:		100 - 740 MCCURDY ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 2P7

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXARIA CORP.
		DATE OF NAME CHANGE:	20080229

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lexaria Corp.
		DATE OF NAME CHANGE:	20051229
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lxrp_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:lxrp="http://lxrp.com/20230508"><head><title>lxrp_8K.htm</title><!--Document Created by XBRLMaster--><meta http-equiv="Content-Type" content="text/html" /></head><body style="text-align:justify;font:10pt times new roman"><div style='display:none;text-align:justify;font:10pt times new roman;margin-left:7%;margin-right:7%;' id='XBRLDIV'><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2023-05-08to2023-05-08">0001348362</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="From2023-05-08to2023-05-08" format="ixt:booleanfalse">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type='simple' xlink:href='lxrp-20230508.xsd'></link:schemaRef></ix:references><ix:resources><xbrli:context id="From2023-05-08to2023-05-08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001348362</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-08</xbrli:startDate><xbrli:endDate>2023-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 5px solid;"></td></tr><tr><td style="BORDER-BOTTOM: 2px solid;"></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>UNITED STATES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Washington, D.C. 20549</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt">FORM <ix:nonNumeric contextRef="From2023-05-08to2023-05-08" name="dei:DocumentType">8-K</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CURRENT REPORT</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Date of Report (Date of earliest event reported): <strong><ix:nonNumeric contextRef="From2023-05-08to2023-05-08" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen">May 8, 2023</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt"><ix:nonNumeric contextRef="From2023-05-08to2023-05-08" name="dei:EntityRegistrantName">Lexaria Bioscience Corp.</ix:nonNumeric></span></strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Exact name of registrant as specified in its charter)</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2023-05-08to2023-05-08" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen">Nevada</ix:nonNumeric></strong></p></td><td style="width:5%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2023-05-08to2023-05-08" name="dei:EntityFileNumber">001-39874</ix:nonNumeric></strong></p></td><td style="width:5%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2023-05-08to2023-05-08" name="dei:EntityTaxIdentificationNumber">20-2000871</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(State or other jurisdiction</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">of incorporation)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Commission</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">File Number)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(IRS Employer</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">IdentifiCAtion No.)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2023-05-08to2023-05-08" name="dei:EntityAddressAddressLine1">100-740 McCurdy Road</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2023-05-08to2023-05-08" name="dei:EntityAddressCityOrTown">Kelowna</ix:nonNumeric>, <ix:nonNumeric contextRef="From2023-05-08to2023-05-08" name="dei:EntityAddressStateOrProvince">BC</ix:nonNumeric> <ix:nonNumeric contextRef="From2023-05-08to2023-05-08" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen">Canada</ix:nonNumeric> <ix:nonNumeric contextRef="From2023-05-08to2023-05-08" name="dei:EntityAddressPostalZipCode">V1X 2P7</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Address of principal executive offices, including Zip Code)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Registrant&#8217;s telephone number, including area code:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(<ix:nonNumeric contextRef="From2023-05-08to2023-05-08" name="dei:CityAreaCode">250</ix:nonNumeric>) <ix:nonNumeric contextRef="From2023-05-08to2023-05-08" name="dei:LocalPhoneNumber">765-6424</ix:nonNumeric></strong>&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>N/A</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Former name or former address, if changed since last report)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2023-05-08to2023-05-08" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2023-05-08to2023-05-08" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2023-05-08to2023-05-08" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2023-05-08to2023-05-08" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:40%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Title of each class:</strong></p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Trading Symbol(s):</strong></p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:40%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Name of each exchange on which registered:</strong></p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2023-05-08to2023-05-08" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2023-05-08to2023-05-08" name="dei:TradingSymbol">LEXX</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">The <ix:nonNumeric contextRef="From2023-05-08to2023-05-08" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Capital Market</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants to Purchase Common Stock</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">LEXXW</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">The Nasdaq Capital Market</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">Emerging growth company <ix:nonNumeric contextRef="From2023-05-08to2023-05-08" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 2px solid;"></td></tr><tr><td style="BORDER-BOTTOM: 5px solid;"></td></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="TEXT-INDENT: 0px;"></td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Item 1.01 Entry into a Material Definitive Agreement.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 8, 2023, Lexaria Bioscience Corp. (the &#8220;Company&#8221;) entered into a placement agency agreement dated as of May 8, 2023 (the &#8220;PAA&#8221;) with Maxim Group LLC (the &#8220;Placement Agent&#8221;) in connection with an offering of an aggregate of 2,106,000 Units (the &#8220;Offering&#8221;), each Unit consisting of one share (the &#8220;Shares&#8221;) of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), and one warrant to purchase one share of Common Stock (the &#8220;Warrants&#8221;). The public offering price was $0.95 per Unit, before deducting placement agent fees and estimated offering expenses. The Offering is expected to close on May 11, 2023, subject to customary closing conditions. The components of the Units were issued separately and are immediately separable upon issuance. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Warrants are immediately exercisable at a price of $0.95 per share and will expire on the five (5) year anniversary of May 11, 2023, the original issuance date. In addition, a holder may also effect a &#8220;cashless&#8221; exercise for the number of shares of common stock to be determined according to a formula set forth in the Warrant if at the time of the exercise of the Warrant, there is no effective registration statement or the prospectus contained in an effective registration statement is not available for the issuance of the underlying shares to the holder. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to the PAA, the Company agreed to pay the Placement Agent a cash placement fee equal to 7.0% of the gross proceeds of the Offering, plus the reimbursement of up to $70,000 of legal fees.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 8, 2023, the Company also entered into a security purchase agreement (the &#8220;Purchase Agreement&#8221;) with certain institutional investors named therein (the &#8220;Purchasers&#8221;) in connection with the Offering. Under the Purchase Agreement, the Purchasers agreed to subscribe for up to an aggregate of $247,000 of Units. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The&#160;Units, the Shares, the&#160;Warrants, and the shares of Common Stock issuable upon exercise of the Warrants were offered by the Company pursuant to a Registration Statement on Form S-1, as amended (File No. 333-271096), initially filed on April 3, 2023, with the Securities and Exchange Commission under the&#160;Securities Act of 1933, as amended, and declared effective on May 8, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Purchase Agreement and PAA contain customary representations, warranties, and agreements by the Company, customary conditions to closing, and indemnification obligations of the Company, the Placement Agent and the Purchasers. The representations, warranties and covenants contained in the Purchase Agreement and PAA were made only for purposes of such agreements and as of a specific date, were solely for the benefit of the parties to such agreements, and may be subject to limitations agreed upon by the contracting parties.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In conjunction with the closing of the Offering, the Company expects to enter into a Warrant Agency Agreement with Computershare Inc. and Computershare Trust Company, N.A. (&#8220;Computershare&#8221;), pursuant to which Computershare will act as warrant agent with respect to the Warrants issued by the Company in the Offering. &#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">A copy of the form of Warrant is filed hereto as Exhibit 4.1. Copies of the Purchase Agreement and PAA are filed hereto as Exhibits 10.1 and 10.2, respectively. A copy of the form of Warrant Agency Agreement is filed hereto as Exhibit 4.2. The foregoing descriptions of the terms of the Warrants, Purchase Agreement, PAA and Warrant Agency Agreement are qualified in their entirety by reference to such exhibits.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;<strong>Item 8.01 Other Events.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 8, 2023, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Forward-Looking Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This current report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (&#8220;PSLRA&#8221;). Such forward-looking statements include but are not limited to statements about the Offering and other statements that are not historical facts. These forward-looking statements are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected, including but not limited to the risks that the Offering does not occur when expected or at all because required conditions to closing are not satisfied on a timely basis or at all. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management&#8217;s current estimates, projections, expectations and beliefs. The Company undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Item 9.01 Financial Statements and Exhibits. </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:8%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exhibit No.</strong></p></td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Description</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/1348362/000164033423000723/lxrp_ex45.htm">4.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1348362/000164033423000723/lxrp_ex45.htm">Form of Warrant (Incorporated by reference to Exhibit 4.5 to the Registration Statement on Form S-1 filed with the SEC on April 28, 2023)</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="MARGIN: 0px; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/1348362/000164033423000723/lxrp_ex109.htm">4.2</a></p></td><td><p style="margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1348362/000164033423000723/lxrp_ex109.htm">Form of Warrant Agency Agreement (Incorporated by reference to Exhibit 10.9 to the Registration Statement on Form S-1 filed with the SEC on April 28, 2023)</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><a href="http://www.sec.gov/Archives/edgar/data/1348362/000164033423000723/lxrp_ex108.htm">10.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1348362/000164033423000723/lxrp_ex108.htm">Form of Securities Purchase Agreement (Incorporated by reference to Exhibit 10.8 to the Registration Statement on Form S-1 filed with the SEC on April 28, 2023)</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><a href="lxrp_ex102.htm">10.2</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="lxrp_ex102.htm">Placement Agency Agreement </a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><a href="lxrp_ex991.htm">99.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="lxrp_ex991.htm">Press Release dated May 8, 2023</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">104</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;SIGNATURES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>LEXARIA BIOSCIENCE CORP.</strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="width:50%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:35%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Date: May 10, 2023</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ Christopher Bunka</em></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Christopher Bunka</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Executive Officer</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>lxrp_ex102.htm
<DESCRIPTION>PLACEMENT AGENCY AGREEMENT
<TEXT>
<html><head><title>lxrp_ex102.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 10.2</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PLACEMENT AGENCY AGREEMENT</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong></strong>&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:70%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">May 8, 2023</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Maxim Group LLC</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">300 Park Avenue, 16<sup style="vertical-align:super">th</sup> Floor</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">New York, NY 10022</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Ladies and Gentlemen:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Subject to the terms and conditions herein (this &#8220;<u>Agreement</u>&#8221;), Lexaria Bioscience Corp., a Nevada corporation (the &#8220;<u>Company</u>&#8221;), hereby agrees to sell up to an aggregate of $2,000,7000 of registered units (the &#8220;<u>Units</u>&#8221;) of the Company, each Unit consisting of either (a) one share (the &#8220;<u>Shares</u>&#8221;) of the Company&#8217;s common stock $0.001 par value per share (the &#8220;<u>Common Stock</u>&#8221;), and one common Warrant to purchase one share of Common Stock (the <u>&#8220;Common Warrants</u>&#8221;) (the <u>&#8220;Common Unit</u>&#8221;) or (b) one pre-funded common stock purchase warrant to purchase one share of Common Stock (the &#8220;<u>Pre-Funded Warrants</u>&#8221;), one Common Warrant (the &#8220;<u>Pre-Funded Unit</u>&#8221;) (the shares of Common Stock underlying the Pre-Funded Warrants and the Warrants, the &#8220;<u>Warrant Shares</u>&#8221;, and the Shares, the Pre-Funded Warrants, the Warrants and the Warrant Shares, the &#8220;<u>Securities</u>&#8221;) directly to various investors (each, an &#8220;<u>Investor</u>&#8221; and, collectively, the &#8220;<u>Investors</u>&#8221;) through Maxim Group LLC as placement agent (the &#8220;<u>Placement Agent</u>&#8221;). The documents executed and delivered by the Company and the Investors in connection with the Offering (as defined below), including, without limitation, a securities purchase agreement (the &#8220;<u>Purchase Agreement</u>&#8221;), shall be collectively referred to herein as the &#8220;<u>Transaction Documents</u>.&#8221; The purchase price to the Investors for each Common Unit is $0.95, the purchase price to the Investors for each Pre-Funded Unit is $0.9499 the exercise price to the Investor for each share of Common Stock issuable upon exercise of the Pre-Funded Warrants is $0.0001, and the exercise price to the Investors for each share of Common Stock issuable upon exercise of the Warrants is $0.95. The Placement Agent may retain other brokers or dealers to act as sub-agents or selected-dealers on its behalf in connection with the Offering.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Company hereby confirms its agreement with the Placement Agent as follows:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Section 1. </strong><strong>Agreement to Act as Placement Agent</strong>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(a) On the basis of the representations, warranties and agreements of the Company herein contained, and subject to all the terms and conditions of this Agreement, the Placement Agent shall be the exclusive placement agent in connection with the offering and sale by the Company of the Securities pursuant to the Company&#8217;s registration statement on Form S-1 (File No. 333-271096) (and including any registration statement prepared and filed by the Company in accordance with Rule 462(b) pursuant to the Securities Act) (the &#8220;<u>Registration Statement</u>&#8221;), with the terms of such offering (the &#8220;<u>Offering</u>&#8221;) to be subject to market conditions and negotiations between the Company, the Placement Agent and the prospective Investors. The Placement Agent will act on a reasonable best efforts basis and the Company agrees and acknowledges that there is no guarantee of the successful placement of the Securities, or any portion thereof, in the prospective Offering. Under no circumstances will the Placement Agent or any of its &#8220;Affiliates&#8221; (as defined below) be obligated to underwrite or purchase any of the Securities for its own account or otherwise provide any financing. The Placement Agent shall act solely as the Company&#8217;s agent and not as principal. The Placement Agent shall have no authority to bind the Company with respect to any prospective offer to purchase Securities and the Company shall have the sole right to accept offers to purchase Securities and may reject any such offer, in whole or in part. Subject to the terms and conditions hereof, payment of the purchase price for, and delivery of, the Securities shall be made at one or more closings (each a &#8220;<u>Closing</u>&#8221; and the date on which each Closing occurs, a &#8220;<u>Closing Date</u>&#8221;). The Closing of the issuance of the Securities shall occur via &#8220;Delivery Versus Payment&#8221;, i.e., on the Closing Date, the Company shall issue the Securities directly to the account designated by the Placement Agent and, upon receipt of such Securities, the Placement Agent shall electronically deliver such Securities to the applicable Investor and payment shall be made by the Placement Agent (or its clearing firm) by wire transfer to the Company. As compensation for services rendered, on each Closing Date, the Company shall pay to the Placement Agent the fees and expenses set forth below:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 90px; TEXT-INDENT: 45px; text-align:justify;">(i) A cash fee equal to 7.0% of the gross proceeds received by the Company from the sale of the Securities at the closing of the Offering (the &#8220;<u>Closing</u>&#8221;).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 90px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 90px; TEXT-INDENT: 45px; text-align:justify;">(ii) The Company also agrees to reimburse Placement Agent&#8217;s expenses up to a maximum of $70,000, unless otherwise agreed by the Company and the Placement Agent, payable immediately upon the Closing of the Offering.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 90px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">1</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(b) The term of the Placement Agent&#8217;s exclusive engagement will be as set forth in the Engagement Agreement (as defined below). Notwithstanding anything to the contrary contained herein, the provisions concerning confidentiality, indemnification and contribution contained herein and the Company&#8217;s obligations contained in the indemnification provisions will survive any expiration or termination of this Agreement, and the Company&#8217;s obligation to pay fees actually earned and payable and to reimburse expenses actually incurred and reimbursable pursuant to Section 1 hereof and which are permitted to be reimbursed under FINRA Rule 5110(g)(4)(A), will survive any expiration or termination of this Agreement. Nothing in this Agreement shall be construed to limit the ability of the Placement Agent or its Affiliates to pursue, investigate, analyze, invest in, or engage in investment banking, financial advisory or any other business relationship with Persons (as defined below) other than the Company. As used herein (i) &#8220;Persons&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind and (ii) &#8220;Affiliate&#8221; means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and construed under Rule 405 under the Securities Act of 1933, as amended (the &#8220;<u>Securities Act</u>&#8221;).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Section 2. </strong><strong>Representations, Warranties and Covenants of the Company</strong>. The Company hereby represents, warrants and covenants to the Placement Agent as of the date hereof, and as of each Closing Date, as follows:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(a) <u>Securities Law Filings</u>. The Company has filed with the Securities and Exchange Commission (the &#8220;<u>Commission</u>&#8221;) the Registration Statement under the Securities Act, which was filed on April 3, 2023, as amended, and declared effective on May 8, 2023 for the registration of the Securities under the Securities Act. Following the determination of pricing among the Company and the prospective Investors introduced to the Company by Placement Agent, the Company will file with the Commission pursuant to Rules 430A and 424(b) under the Securities Act, and the rules and regulations (the &#8220;<u>Rules and Regulations</u>&#8221;) of the Commission promulgated thereunder, a final prospectus relating to the placement of the Securities, their respective pricings and the plan of distribution thereof and will advise the Placement Agent of all further information (financial and other) with respect to the Company required to be set forth therein. Such registration statement, at any given time, including the exhibits thereto filed at such time, as amended at such time, is hereinafter called the &#8220;<u>Registration Statement</u>&#8221;; such prospectus in the form in which it appears in the Registration Statement at the time of effectiveness is hereinafter called the &#8220;<u>Preliminary Prospectus</u>&#8221;; and the final prospectus, in the form in which it will be filed with the Commission pursuant to Rules 430A and/or 424(b) (including the Preliminary Prospectus as it may be amended or supplemented) is hereinafter called the &#8220;<u>Final Prospectus</u>.&#8221; The Registration Statement at the time it originally became effective is hereinafter called the &#8220;<u>Original Registration Statement</u>.&#8221; Any reference in this Agreement to the Registration Statement, the Original Registration Statement, the Preliminary Prospectus or the Final Prospectus shall be deemed to refer to and include the documents incorporated by reference therein (the &#8220;<u>Incorporated Documents</u>&#8221;), if any, which were or are filed under the Securities Exchange Act of 1934, as amended (the &#8220;<u>Exchange Act</u>&#8221;), at any given time, as the case may be; and any reference in this Agreement to the terms &#8220;amend,&#8221; &#8220;amendment&#8221; or &#8220;supplement&#8221; with respect to the Registration Statement, the Original Registration Statement, the Preliminary Prospectus or the Final Prospectus shall be deemed to refer to and include the filing of any document under the Exchange Act after the date of this Agreement, or the issue date of the Preliminary Prospectus or the Final Prospectus, as the case may be, deemed to be incorporated therein by reference. All references in this Agreement to financial statements and schedules and other information which is &#8220;contained,&#8221; &#8220;included,&#8221; &#8220;described,&#8221; &#8220;referenced,&#8221; &#8220;set forth&#8221; or &#8220;stated&#8221; in the Registration Statement, the Preliminary Prospectus or the Final Prospectus (and all other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information which is or is deemed to be incorporated by reference in the Registration Statement, the Preliminary Prospectus or the Final Prospectus, as the case may be. As used in this paragraph and elsewhere in this Agreement, &#8220;<u>Time of Sale Disclosure Package</u>&#8221; means the Preliminary Prospectus, any securities purchase agreement between the Company and the Investors, the final terms of the Offering provided to the Investors (orally or in writing) and any issuer free writing prospectus as defined in Rule 433 of the Act (each, an &#8220;<u>Issuer Free Writing Prospectus</u>&#8221;), if any, that the parties hereto shall hereafter expressly agree in writing to treat as part of the Time of Sale Disclosure Package. The term &#8220;<u>any Prospectus</u>&#8221; shall mean, as the context requires, the Preliminary Prospectus, the Final Prospectus, and any supplement to either thereof. The Company has not received any notice that the Commission has issued or intends to issue a stop order suspending the effectiveness of the Registration Statement or the use of the Preliminary Prospectus or any prospectus supplement or intends to commence a proceeding for any such purpose.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(b) <u>Assurances</u>. The Original Registration Statement, as amended, (and any further documents to be filed with the Commission) contains all exhibits and schedules as required by the Securities Act. Each of the Registration Statement and any post-effective amendment thereto, at the time it became effective, complied in all material respects with the Securities Act and the applicable Rules and Regulations and did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. The Final Prospectus, as of its date, compiled or will comply in all material respects with the Securities Act and the applicable Rules and Regulations. The Final Prospectus, as amended or supplemented, did not and will not contain as of the date thereof any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The Incorporated Documents, when they were filed with the Commission, conformed in all material respects to the requirements of the Exchange Act and the applicable Rules and Regulations promulgated thereunder, and none of such documents, when they were filed with the Commission, contained any untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein (with respect to Incorporated Documents incorporated by reference in the Final Prospectus), in light of the circumstances under which they were made not misleading. No post-effective amendment to the Registration Statement reflecting any facts or events arising after the date thereof which represent, individually or in the aggregate, a fundamental change in the information set forth therein is required to be filed with the Commission. Except for this Agreement and the Transaction Documents, there are no documents required to be filed with the Commission in connection with the transaction contemplated hereby that (x) have not been filed as required pursuant to the Securities Act or (y) will not be filed within the requisite time period. Except for this Agreement and the Transaction Documents, there are no contracts or other documents required to be described in the Final Prospectus, or to be filed as exhibits or schedules to the Registration Statement, which have not been described or filed as required.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(c) <u>Offering Materials</u>. Neither the Company nor any of its directors and officers has distributed and none of them will distribute, prior to each Closing Date, any offering material in connection with the offering and sale of the Securities other than the Time of Sale Disclosure Package.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(d) <u>Authorization; Enforcement</u>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and the Time of Sale Disclosure Package and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of each of this Agreement by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, the Company&#8217;s Board of Directors (the &#8220;<u>Board of Directors</u>&#8221;) or the Company&#8217;s shareholders in connection therewith other than in connection with the Required Approvals (as defined in the Purchase Agreement). This Agreement has been duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#8217; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(e) <u>No Conflicts</u>. The execution, delivery and performance by the Company of this Agreement and the transactions contemplated pursuant to the Time of Sale Disclosure Package, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby to which it is a party do not and will not (i) conflict with or violate any provision of the Company&#8217;s or any Subsidiary&#8217;s certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect, as defined in the Securities Purchase Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(f) <u>Certificates</u>. Any certificate signed by an officer of the Company and delivered to the Placement Agent or to counsel for the Placement Agent shall be deemed to be a representation and warranty by the Company to the Placement Agent as to the matters set forth therein.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(g) <u>Reliance</u>. The Company acknowledges that the Placement Agent will rely upon the accuracy and truthfulness of the foregoing representations and warranties and hereby consents to such reliance.<strong> </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(h) <u>Forward-Looking Statements</u>. No forward-looking statements (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act) contained in the Time of Sale Disclosure Package has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.<strong></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(i) <u>Statistical or Market-Related Data</u>. Any statistical, industry-related and market-related data included or incorporated by reference in the Time of Sale Disclosure Package, are based on or derived from sources that the Company reasonably and in good faith believes to be reliable and accurate, and such data agree with the sources from which they are derived.<strong></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(j) <u>Certain Fees; FINRA Affiliations</u>. Except as set forth in the Registration Statement and Prospectus, no brokerage or finder&#8217;s fees or commissions are or will be payable by the Company, any Subsidiary or Affiliate of the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. There are no other arrangements, agreements or understandings of the Company or, to the Company&#8217;s knowledge, any of its shareholders that may affect the Placement Agent&#8217;s compensation, as determined by FINRA. Other than payments to the Placement Agent for this Offering or as set forth in the Registration Statement and Prospectus, the Company has not made and has no agreements, arrangements or understanding to make any direct or indirect payments (in cash, securities or otherwise) to: (i) any person, as a finder&#8217;s fee, consulting fee or otherwise, in consideration of such person raising capital for the Company or introducing to the Company persons who raised or provided capital to the Company; (ii) any FINRA member participating in the offering as defined in FINRA Rule 5110 (a &#8220;Participating Member&#8221;); or (iii) any person or entity that has any direct or indirect affiliation or association with any Participating Member, within the 180-day period preceding the initial filing of the Registration Statement through the 60-day period after the Effective Date. None of the net proceeds of the Offering will be paid by the Company to any Participating Member or its affiliates, except as specifically authorized herein. To the Company&#8217;s knowledge, no officer, director or any beneficial owner of 10% or more of the Company&#8217;s Common Stock or Common Stock Equivalents (as defined in the Securities Purchase Agreement) has any direct or indirect affiliation or association with any Participating Member in the Offering. Except for securities purchased on the open market, no Company Affiliate is an owner of stock or other securities of any Participating Member. No Company Affiliate has made a subordinated loan to any Participating Member. No proceeds from the sale of the Securities (excluding Placement Agent compensation as disclosed in the Registration Statement and the Prospectus) will be paid to any Participating Member, any persons associated with a Participating Member or an affiliate of a Participating Member. Except as disclosed in the Prospectus, the Company has not issued any warrants or other securities or granted any options, directly or indirectly, to the Placement Agent within the 180-day period prior to the initial filing date of the Prospectus. Except for securities issued to the Placement Agent as disclosed in the Prospectus, no person to whom securities of the Company have been privately issued within the 180-day period prior to the initial filing date of the Prospectus is a Participating Member, is a person associated with a Participating Member or is an affiliate of a Participating Member. To the Company&#8217;s knowledge, no Participating Member in the Offering has a conflict of interest with the Company. For this purpose, a &#8220;conflict of interest&#8221; exists when a Participating Member, the parent or affiliate of a Participating Member or any person associated with a Participating Member in the aggregate beneficially own 10% or more of the Company&#8217;s outstanding subordinated debt or common equity, or 10% or more of the Company&#8217;s preferred equity. &#8220;FINRA member participating in the Offering&#8221; includes any associated person of a Participating Member in the Offering, any member of such associated person&#8217;s immediate family and any affiliate of a Participating Member in the Offering. When used in this Section 3.1(j) the term &#8220;affiliate of a FINRA member&#8221; or &#8220;affiliated with a FINRA member&#8221; means an entity that controls, is controlled by or is under common control with a FINRA member. The Company will advise the Placement Agent and its legal counsel, Ellenoff Grossman &amp; Schole LLP (the &#8220;<u>Placement Agent Counsel</u>&#8221;) if it learns that any officer, director or owner of 10% or more of the Company&#8217;s outstanding Common Stock or Common Stock Equivalents is or becomes an affiliate or associated person of a Participating Member.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(k) <u>Board of Directors</u>. The Board of Directors is comprised of the persons set forth under the heading of the Company&#8217;s Annual Report on Form 10-K captioned &#8220;Directors, Executive Officers and Corporate Governance.&#8221; The qualifications of the persons serving as board members and the overall composition of the Board of Directors comply with the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder applicable to the Company and the rules of the Nasdaq Capital Market (the &#8220;<u>Trading Market</u>&#8221;). In addition, at least a majority of the persons serving on the Board of Directors qualify as &#8220;independent&#8221; as defined under the rules of the Trading Market.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(l) <u>D&amp;O Questionnaires</u>. To the Company&#8217;s knowledge, all information contained in the questionnaires most recently completed by each of the Company&#8217;s directors and officers is true and correct in all respects and the Company has not become aware of any information which would cause the information disclosed in such questionnaires to become inaccurate and incorrect.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(m) <u>Insurance</u>. As soon as practicable after the Closing and on a best efforts basis, the Company agrees to apply to increase its current directors and officers insurance coverage to an aggregate amount of $2 million and promptly secure such increased directors and officers insurance coverage. The Company will then take all action reasonably necessary to maintain such increased directors and officers insurance coverage.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(n) <u>Representations and Warranties Incorporated by Reference</u>. Each of the representations and warranties (together with any related disclosure schedules thereto) made to the Investors in the Purchase Agreement is hereby incorporated herein by reference (as though fully restated herein) and is hereby made to, and in favor of, the Placement Agent.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Section 3. </strong><strong>Delivery and Payment</strong>. Each Closing shall occur at the offices of the Placement Agent Counsel at 1345 Avenue of the Americas, New York, New York 10105 (or at such other place as shall be agreed upon by the Placement Agent and the Company). Subject to the terms and conditions hereof, at each Closing payment of the purchase price for the Securities sold on such Closing Date shall be made by Federal Funds wire transfer, against delivery of such Securities, and such Securities shall be registered in such name or names and shall be in such denominations, as the Placement Agent may request at least one business day before the time of purchase (as defined below).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Deliveries of the documents with respect to the purchase of the Securities, if any, shall be made at the offices of Placement Agent Counsel. All actions taken at a Closing shall be deemed to have occurred simultaneously.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Section 4. </strong><strong>Covenants and Agreements of the Company</strong>. The Company further covenants and agrees with the Placement Agent as follows:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(a) <u>Registration Statement Matters</u>. The Company will advise the Placement Agent promptly after it receives notice thereof of the time when any amendment to the Registration Statement has been filed or becomes effective or any supplement to the Final Prospectus has been filed and will furnish the Placement Agent with copies thereof. The Company will file promptly all reports and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Section 13(a), 14 or 15(d) of the Exchange Act subsequent to the date of any Prospectus and for so long as the delivery of a prospectus is required in connection with the Offering. The Company will advise the Placement Agent, promptly after it receives notice thereof (i) of any request by the Commission to amend the Registration Statement or to amend or supplement any Prospectus or for additional information, (ii) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto or any order directed at any Incorporated Document, if any, or any amendment or supplement thereto or any order preventing or suspending the use of the Preliminary Prospectus or the Final Prospectus or any prospectus supplement or any amendment or supplement thereto or any post-effective amendment to the Registration Statement, of the suspension of the qualification of the Securities for offering or sale in any jurisdiction, of the institution or threatened institution of any proceeding for any such purpose, or of any request by the Commission for the amending or supplementing of the Registration Statement or a Prospectus or for additional information, (iii) of the issuance by any state securities commission of any proceedings for the suspension of the qualification of the Securities for offering or sale in any jurisdiction or of the initiation, or the threatening, of any proceeding for that purpose; (iv) of the mailing and delivery to the Commission for filing of any amendment or supplement to the Registration Statement or Prospectus; (v) of the receipt of any comments or request for any additional information from the Commission; and (vi) of the happening of any event during the period described in this Section 4(a) that, in the judgment of the Company, makes any statement of a material fact made in the Registration Statement or the Prospectus untrue or that requires the making of any changes in the Registration Statement or the Prospectus in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The Company shall use its best efforts to prevent the issuance of any such stop order or prevention or suspension of such use. If the Commission shall enter any such stop order or order or notice of prevention or suspension at any time, the Company will use its best efforts to obtain the lifting of such order at the earliest possible moment, or will file a new registration statement and use its best efforts to have such new registration statement declared effective as soon as practicable. Additionally, the Company agrees that it shall comply with the provisions of Rules 424(b), 430A, 430B and 430C, as applicable, under the Securities Act, including with respect to the timely filing of documents thereunder, and will use its reasonable efforts to confirm that any filings made by the Company under such Rule 424(b) are received in a timely manner by the Commission.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(b) <u>Blue Sky Compliance</u>. The Company will cooperate with the Placement Agent and the Investors in endeavoring to qualify the Securities for sale under the securities laws of such jurisdictions (United States and foreign) as the Placement Agent and the Investors may reasonably request and will make such applications, file such documents, and furnish such information as may be reasonably required for that purpose, provided the Company shall not be required to qualify as a foreign corporation or to file a general consent to service of process in any jurisdiction where it is not now so qualified or required to file such a consent, and provided further that the Company shall not be required to produce any new disclosure document. The Company will, from time to time, prepare and file such statements, reports and other documents as are or may be required to continue such qualifications in effect for so long a period as the Placement Agent may reasonably request for distribution of the Securities. The Company will advise the Placement Agent promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Securities for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company shall use its best efforts to obtain the withdrawal thereof at the earliest possible moment.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(c) <u>Amendments and Supplements to a Prospectus and Other Matters</u>. The Company will comply with the Securities Act and the Exchange Act, and the rules and regulations of the Commission thereunder, so as to permit the completion of the distribution of the Securities as contemplated in this Agreement, the Incorporated Documents and any Prospectus. If during the period in which a prospectus is required by law to be delivered in connection with the distribution of Securities contemplated by the Incorporated Documents or any Prospectus (the &#8220;<u>Prospectus Delivery Period</u>&#8221;), any event shall occur as a result of which, in the judgment of the Company or in the opinion of the Placement Agent or counsel for the Placement Agent, it becomes necessary to amend or supplement the Incorporated Documents or any Prospectus in order to make the statements therein, in the light of the circumstances under which they were made, as the case may be, not misleading, or if it is necessary at any time to amend or supplement the Incorporated Documents or any Prospectus or to file under the Exchange Act any Incorporated Document to comply with any law, the Company will promptly prepare and file with the Commission, and furnish at its own expense to the Placement Agent and to dealers, an appropriate amendment to the Registration Statement or supplement to the Registration Statement, the Incorporated Documents or any Prospectus that is necessary in order to make the statements in the Incorporated Documents and any Prospectus as so amended or supplemented, in the light of the circumstances under which they were made, as the case may be, not misleading, or so that the Registration Statement, the Incorporated Documents or any Prospectus, as so amended or supplemented, will comply with law. Before amending the Registration Statement or supplementing the Incorporated Documents or any Prospectus in connection with the Offering, the Company will furnish the Placement Agent with a copy of such proposed amendment or supplement and will not file any such amendment or supplement to which the Placement Agent reasonably objects.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(d) <u>Copies of any Amendments and Supplements to a Prospectus</u>. The Company will furnish the Placement Agent, without charge, during the period beginning on the date hereof and ending on the later of the last Closing Date of the Offering, as many copies of any Prospectus or prospectus supplement and any amendments and supplements thereto, as the Placement Agent may reasonably request.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(e) <u>Free Writing Prospectus</u>. The Company covenants that it will not, unless it obtains the prior written consent of the Placement Agent, make any offer relating to the Securities that would constitute a Company Free Writing Prospectus or that would otherwise constitute a &#8220;<u>free writing prospectus</u>&#8221; (as defined in Rule 405 of the Securities Act) required to be filed by the Company with the Commission or retained by the Company under Rule 433 of the Securities Act. In the event that the Placement Agent expressly consents in writing to any such free writing prospectus (a &#8220;<u>Permitted Free Writing Prospectus</u>&#8221;), the Company covenants that it shall (i) treat each Permitted Free Writing Prospectus as an Company Free Writing Prospectus, and (ii) comply with the requirements of Rule 164 and 433 of the Securities Act applicable to such Permitted Free Writing Prospectus, including in respect of timely filing with the Commission, legending and record keeping.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(f) <u>Transfer Agent</u>. The Company will maintain, at its expense, a registrar and transfer agent for the Shares.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(g) <u>[Reserved]</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(h) <u>Periodic Reporting Obligations</u>. During the Prospectus Delivery Period, the Company will duly file, on a timely basis, with the Commission and the Trading Market all reports and documents required to be filed under the Exchange Act within the time periods and in the manner required by the Exchange Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(i) <u>Additional Documents</u>. The Company will enter into any subscription, purchase or other customary agreements as the Placement Agent or the Investors deem necessary or appropriate to consummate the Offering, all of which will be in form and substance reasonably acceptable to the Placement Agent and the Investors. The Company agrees that the Placement Agent may rely upon, and each is a third party beneficiary of, the representations and warranties, and applicable covenants, set forth in any such purchase, subscription or other agreement with Investors in the Offering.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(j) <u>No Manipulation of Price</u><em>. </em>Neither the Company, nor to its knowledge, any of its employees, directors or shareholders, has taken or will take, directly or indirectly, any action designed to or that has constituted or that might reasonably be expected to cause or result in, under the Exchange Act, or otherwise stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(k) <u>Acknowledgment</u>. The Company acknowledges that any advice given by the Placement Agent to the Company is solely for the benefit and use of the Board of Directors of the Company and may not be used, reproduced, disseminated, quoted or referred to, without the Placement Agent&#8217;s prior written consent.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(l) <u>Announcement of Offering</u>. The Company acknowledges and agrees that the Placement Agent may, subsequent to the Closing, make public its involvement with the Offering.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(m) <u>Reliance on Others</u>. The Company confirms that it will rely on its own counsel and accountants for legal and accounting advice.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(n) <u>Research Matters</u>. By entering into this Agreement, the Placement Agent does not provide any promise, either explicitly or implicitly, of favorable or continued research coverage of the Company and the Company hereby acknowledges and agrees that the Placement Agent&#8217;s selection as a placement agent for the Offering was in no way conditioned, explicitly or implicitly, on the Placement Agent providing favorable or any research coverage of the Company. In accordance with FINRA Rule 2241(b)(2), the parties acknowledge and agree that the Placement Agent has not directly or indirectly offered favorable research, a specific rating or a specific price target, or threatened to change research, a rating or a price target, to the Company or inducement for the receipt of business or compensation. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against the Placement Agent with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by the Placement Agent&#8217;s investment banking divisions. The Company acknowledges that the Placement Agent is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short position in debt or equity securities of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">8</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(o) <u>Subsequent Equity Sales</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 90px; TEXT-INDENT: 45px; text-align:justify;">(i) From the date hereof until ninety days (90) after the Closing Date (as defined in the Warrants), neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than the Prospectus or filing a registration statement on Form S-8 in connection with any employee benefit plan, in each case without prior written consent of the Placement Agent.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 90px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 90px; TEXT-INDENT: 45px; text-align:justify;">(ii) From the date hereof until one hundred eighty (180) days after the Closing Date (as defined in the Warrants), the Company shall be prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination of units thereof) involving a Variable Rate Transaction. &#8220;Variable Rate Transaction&#8221; means a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction under, any agreement, including, but not limited to, an equity line of credit or an &#8220;at-the-market offering&#8221;, whereby the Company may issue securities at a future determined price; <u>provided</u>, <u>however</u>, that ninety (90) days after the Closing Date, the issuance of shares of Common Stock in an &#8220;at the market&#8221; offering with the Placement Agent as sales agent shall not be deemed a Variable Rate Transaction. Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 90px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 90px; TEXT-INDENT: 45px; text-align:justify;">(iii) Notwithstanding the foregoing, this Section 4(o) shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall be an Exempt Issuance. An &#8220;<u>Exempt Issuance</u>&#8221; means the issuance of (a) Common Stock or equity awards to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to the Company, (b) securities upon the exercise or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable or exchangeable for or convertible into Common Stock issued and outstanding on the date of this Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection with automatic price resets, stock splits, adjustments or combinations as set forth in such securities) or to extend the term of such securities and (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities are issued as &#8220;restricted securities&#8221; (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith during the six month period following the Closing Date, and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">9</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 90px; TEXT-INDENT: 45px; text-align:justify;">(iv) If within six (6) months of the Closing, the Company completes any financing of equity, equity-linked, convertible or debt or other capital-raising activity of the Company for which the Placement Agent is not acting as underwriter or placement agent (other than the exercise by any person or entity of any options, warrants or other convertible securities) with any of the investors that were contacted or introduced by the Placement Agent in the Offering, then the Company shall pay to the Placement Agent a commission as described in Section 1(a)(i) herein, in each case only with respect to the portion of such financing received from such investors.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(p) <u>Lock-Up Agreements</u>. The Company shall not amend, modify, waive or terminate any provision of any of the Lock-Up Agreements except to extend the term of the lock-up period and shall enforce the provisions of each Lock-Up Agreement in accordance with its terms. If any party to a Lock-Up Agreement breaches any provision of a Lock-Up Agreement, the Company shall promptly use its best efforts to seek specific performance of the terms of such Lock-Up Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(q) <u>FINRA</u>. The Company shall advise the Placement Agent (who shall make an appropriate filing with FINRA) if it is aware that any officer, director, 10% or greater shareholder of the Company or Person that received the Company&#8217;s unregistered equity securities in the past 180 days is or becomes an affiliate or associated person of a FINRA member firm prior to the earlier of the termination of this Agreement or the 60-day period after the Effective Date</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Section 5. </strong><strong>Conditions of the Obligations of the Placement Agent</strong>. The obligations of the Placement Agent hereunder shall be subject to the accuracy of the representations and warranties on the part of the Company set forth in Section 2 hereof, in each case as of the date hereof and as of each Closing Date as though then made, to the timely performance by each of the Company of its covenants and other obligations hereunder on and as of such dates, and to each of the following additional conditions:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(a) <u>Accountants&#8217; Comfort Letters</u>. On the date hereof, the Placement Agent shall have received, and the Company shall have caused to be delivered to the Placement Agent, a letter from both Davidson &amp; Company LLP (the former independent registered public accounting firm of the Company) and MaloneBailey LLP (the current independent registered public accounting firm of the Company), addressed to the Placement Agent, dated as of the date hereof, in form and substance satisfactory to the Placement Agent. The letter shall not disclose any change in the condition (financial or other), earnings, operations, business or prospects of the Company from that set forth in the Incorporated Documents or the applicable Prospectus or prospectus supplement, which, in the Placement Agent&#8217;s sole judgment, is material and adverse and that makes it, in the Placement Agent&#8217;s sole judgment, impracticable or inadvisable to proceed with the Offering of the Securities as contemplated by such Prospectus.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">10</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(b) <u>Compliance with Registration Requirements; No Stop Order; No Objection from the FINRA.</u> Each Prospectus (in accordance with Rule 424(b)) and &#8220;<u>free writing prospectus</u>&#8221; (as defined in Rule 405 of the Securities Act), if any, shall have been duly filed with the Commission, as appropriate; no stop order suspending the effectiveness of the Registration Statement or any part thereof shall have been issued and no proceeding for that purpose shall have been initiated or threatened by the Commission; no order preventing or suspending the use of any Prospectus shall have been issued and no proceeding for that purpose shall have been initiated or threatened by the Commission; no order having the effect of ceasing or suspending the distribution of the Securities or any other securities of the Company shall have been issued by any securities commission, securities regulatory authority or stock exchange and no proceedings for that purpose shall have been instituted or shall be pending or, to the knowledge of the Company, contemplated by any securities commission, securities regulatory authority or stock exchange; all requests for additional information on the part of the Commission shall have been complied with; and FINRA shall have raised no objection to the fairness and reasonableness of the placement terms and arrangements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(c) <u>Corporate Proceedings</u>. All corporate proceedings and other legal matters in connection with this Agreement, the Registration Statement and each Prospectus, and the registration, sale and delivery of the Securities, shall have been completed or resolved in a manner reasonably satisfactory to the Placement Agent&#8217;s counsel, and such counsel shall have been furnished with such papers and information as it may reasonably have requested to enable such counsel to pass upon the matters referred to in this Section 5.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(d) <u>No Material Adverse Change</u>. Subsequent to the execution and delivery of this Agreement and prior to each Closing Date, in the Placement Agent&#8217;s sole judgment after consultation with the Company, there shall not have occurred any Material Adverse Effect or any material adverse change or development involving a prospective material adverse change in the condition or the business activities, financial or otherwise, of the Company from the latest dates as of which such condition is set forth in the Registration Statement and Prospectus (&#8220;<u>Material Adverse Change</u>&#8221;).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(e) <u>Opinion of Counsels for the Company</u>. The Placement Agent shall have received on each Closing Date (i) the favorable opinion of Sichenzia Ross Ference LLP, counsel to the Company, dated as of such Closing Date, including, without limitation, a negative assurance letter addressed to the Placement Agent and in form and substance satisfactory to the Placement Agent, and (ii) the favorable opinion of FisherBroyles LLP, intellectual property legal counsel to the Company, addressed to the Placement Agent in form and substance satisfactory to the Placement Agent.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(f) <u>Officers&#8217; Certificate</u>. The Placement Agent shall have received on each Closing Date a certificate of the Company, dated as of such Closing Date, signed by the Chief Executive Officer and Chief Financial Officer of the Company, to the effect that, and the Placement Agent shall be satisfied that, the signers of such certificate have reviewed the Registration Statement, the Incorporated Documents, the Prospectus, and this Agreement and to the further effect that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 90px; TEXT-INDENT: 45px; text-align:justify;">(i) The representations and warranties of the Company in this Agreement are true and correct, as if made on and as of such Closing Date, and the Company has complied with all the agreements and satisfied all the conditions on its part to be performed or satisfied at or prior to such Closing Date;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">11</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 90px; TEXT-INDENT: 45px; text-align:justify;">(ii) No stop order suspending the effectiveness of the Registration Statement or the use of the Prospectus has been issued and no proceedings for that purpose have been instituted or are pending or, to the Company&#8217;s knowledge, threatened under the Securities Act; no order having the effect of ceasing or suspending the distribution of the Securities or any other securities of the Company has been issued by any securities commission, securities regulatory authority or stock exchange in the United States and no proceedings for that purpose have been instituted or are pending or, to the knowledge of the Company, contemplated by any securities commission, securities regulatory authority or stock exchange in the United States;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 90px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 90px; TEXT-INDENT: 45px; text-align:justify;">(iii) When the Registration Statement became effective, at the time of sale, and at all times subsequent thereto up to the delivery of such certificate, the Registration Statement and the Incorporated Documents, if any, when such documents became effective or were filed with the Commission, and any Prospectus, contained all material information required to be included therein by the Securities Act and the Exchange Act and the applicable rules and regulations of the Commission thereunder, as the case may be, and in all material respects conformed to the requirements of the Securities Act and the Exchange Act and the applicable rules and regulations of the Commission thereunder, as the case may be, and the Registration Statement and the Incorporated Documents, if any, and any Prospectus, did not and do not include any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading (provided, however, that the preceding representations and warranties contained in this paragraph (iii) shall not apply to any statements or omissions made in reliance upon and in conformity with information furnished in writing to the Company by the Placement Agent expressly for use therein) and, since the effective date of the Registration Statement, there has occurred no event required by the Securities Act and the rules and regulations of the Commission thereunder to be set forth in the Incorporated Documents which has not been so set forth; and</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 90px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 90px; TEXT-INDENT: 45px; text-align:justify;">(iv) Subsequent to the respective dates as of which information is given in the Registration Statement, the Incorporated Documents and any Prospectus, there has not been: (a) any Material Adverse Change; (b) any transaction that is material to the Company and the Subsidiaries taken as a whole, except transactions entered into in the ordinary course of business; (c) any obligation, direct or contingent, that is material to the Company and the Subsidiaries taken as a whole, incurred by the Company or any Subsidiary, except obligations incurred in the ordinary course of business; (d) any material change in the capital stock (except changes thereto resulting from the exercise of outstanding stock options or warrants or conversion of outstanding preferred stock) or outstanding indebtedness of the Company or any Subsidiary; (e) any dividend or distribution of any kind declared, paid or made on the capital stock of the Company; or (f) any loss or damage (whether or not insured) to the property of the Company or any Subsidiary which has been sustained or will have been sustained which has a Material Adverse Effect.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(g) <u>Regulatory Certificate</u>. On the Closing Date, the Placement Agent shall have received a certificate from the Company&#8217;s Chief Executive Officer with respect to certain regulatory matters, dated as of the Closing Date, addressed to the Placement Agent in form and substance satisfactory to the Placement Agent.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">12</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(h) <u>Bring-down Comfort Letters</u><em>. </em>On each Closing Date, the Placement Agent shall have received from Davidson &amp; Company LLP and MaloneBailey LLP, or such other independent registered public accounting firm of the Company, a letter dated as of such Closing Date, in form and substance satisfactory to the Placement Agent, to the effect that they reaffirm the statements made in the letter furnished pursuant to subsection (a) of this Section 5, except that the specified date referred to therein for the carrying out of procedures shall be no more than two business days prior to such Closing Date.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(i) <u>Stock Exchange Listing</u>. The Common Stock shall be registered under the Exchange Act and shall be listed on the Trading Market, and the Company shall not have taken any action designed to terminate, or likely to have the effect of terminating, the registration of the Common Stock under the Exchange Act or delisting or suspending from trading the Common Stock from the Trading Market, nor shall the Company have received any information suggesting that the Commission or the Trading Market is contemplating terminating such registration or listing.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(j) <u>Lock-Up Agreements</u>. On the Closing Date, the Placement Agent shall have received the executed lock-up agreement from each of the Company&#8217;s directors, and executive officers of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(k) <u>Warrant Agency Agreement</u>. On the Closing Date the duly executed warrant agency agreement executed by and between the Company and the transfer agent.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(l) <u>Additional Documents</u>. On or before each Closing Date, the Placement Agent and counsel for the Placement Agent shall have received such information and documents as they may reasonably require for the purposes of enabling them to pass upon the issuance and sale of the Securities as contemplated herein, or in order to evidence the accuracy of any of the representations and warranties, or the satisfaction of any of the conditions or agreements, herein contained.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If any condition specified in this Section 5 is not satisfied when and as required to be satisfied, this Agreement may be terminated by the Placement Agent by notice to the Company at any time on or prior to a Closing Date, which termination shall be without liability on the part of any party to any other party, except that Section 6 (Payment of Expenses), Section 7 (Indemnification and Contribution) and Section 8 (Representations and Indemnities to Survive Delivery) shall at all times be effective and shall survive such termination.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Section 6. </strong><strong>Payment of Expenses</strong>. The Company agrees to pay all costs, fees and expenses incurred by the Company in connection with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including, without limitation: (i) all expenses incident to the issuance, delivery and qualification of the Securities (including all printing and engraving costs); (ii) all fees and expenses of the registrar and transfer agent of the Common Stock; (iii) all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Securities; (iv) all fees and expenses of the Company&#8217;s counsel, independent public or certified public accountants and other advisors; (v) all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Preliminary Prospectus, the Final Prospectus and each prospectus supplement, if any, and all amendments and supplements thereto, and this Agreement; (vi) all filing fees, reasonable attorneys&#8217; fees and expenses incurred by the Company or the Placement Agent in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Securities for offer and sale under the state securities or blue sky laws or the securities laws of any other country, and, if requested by the Placement Agent, preparing and printing a &#8220;<u>Blue Sky Survey</u>,&#8221; an &#8220;<u>International Blue Sky Survey</u>&#8221; or other memorandum, and any supplements thereto, advising the Placement Agent of such qualifications, registrations and exemptions; (vii) if applicable, the filing fees incident to the review and approval by FINRA of the Placement Agent&#8217;s participation in the offering and distribution of the Securities; (viii) the fees and expenses associated with including the Shares and Warrant Shares on the Trading Market; (ix) all costs and expenses incident to the travel and accommodation of the Company&#8217;s and the Placement Agent&#8217;s employees on the &#8220;<u>roadshow</u>,&#8221; if any; and (x) all other fees, costs and expenses referred to in Part II of the Registration Statement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">13</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Section 7. </strong><strong>Indemnification and Contribution</strong>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(a) The Company agrees to indemnify and hold harmless the Placement Agent, its affiliates and each person controlling the Placement Agent<strong> </strong>(within the meaning of Section 15 of the Securities Act), and the directors, officers, agents and employees of the Placement Agent, its affiliates and each such controlling person (the Placement Agent, and each such entity or person. an &#8220;<u>Indemnified Person</u>&#8221;) from and against any losses, claims, damages, judgments, assessments, costs and other liabilities (collectively, the &#8220;<u>Liabilities</u>&#8221;), and shall reimburse each Indemnified Person for all fees and expenses (including the reasonable fees and expenses of one counsel for all Indemnified Persons, except as otherwise expressly provided herein) (collectively, the &#8220;<u>Expenses</u>&#8221;) as they are incurred by an Indemnified Person in investigating, preparing, pursuing or defending any actions, whether or not any Indemnified Person is a party thereto, (i) caused by, or arising out of or in connection with, any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, any Incorporated Document, or any Prospectus or by any omission or alleged omission to state therein a material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading (other than untrue statements or alleged untrue statements in, or omissions or alleged omissions from, information relating to an Indemnified Person furnished in writing by or on behalf of such Indemnified Person expressly for use in the Incorporated Documents) or (ii) otherwise arising out of or in connection with advice or services rendered or to be rendered by any Indemnified Person pursuant to this Agreement, the transactions contemplated thereby or any Indemnified Person&#8217;s actions or inactions in connection with any such advice, services or transactions; <u>provided</u>, <u>however</u>, that, in the case of clause (ii) only, the Company shall not be responsible for any Liabilities or Expenses of any Indemnified Person that are finally judicially determined to have resulted solely from such Indemnified Person&#8217;s (x) gross negligence or willful misconduct in connection with any of the advice, actions, inactions or services referred to above or (y) use of any offering materials or information concerning the Company in connection with the offer or sale of the Securities in the Offering which were not authorized for such use by the Company and which use constitutes gross negligence or willful misconduct. The Company also agrees to reimburse each Indemnified Person for all Expenses as they are incurred in connection with enforcing such Indemnified Person&#8217;s rights under this Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(b) Upon receipt by an Indemnified Person of actual notice of an action against such Indemnified Person with respect to which indemnity may be sought under this Agreement, such Indemnified Person shall promptly notify the Company in writing; provided that failure by any Indemnified Person so to notify the Company shall not relieve the Company from any liability which the Company may have on account of this indemnity or otherwise to such Indemnified Person, except to the extent the Company shall have been prejudiced by such failure. The Company shall, if requested by the Placement Agent, assume the defense of any such action including the employment of counsel reasonably satisfactory to the Placement Agent, which counsel may also be counsel to the Company. Any Indemnified Person shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless: (i) the Company has failed promptly to assume the defense and employ counsel or (ii) the named parties to any such action (including any impeded parties) include such Indemnified Person and the Company, and such Indemnified Person shall have been advised in the reasonable opinion of counsel that there is an actual conflict of interest that prevents the counsel selected by the Company from representing both the Company (or another client of such counsel) and any Indemnified Person; provided that the Company shall not in such event be responsible hereunder for the fees and expenses of more than one firm of separate counsel for all Indemnified Persons in connection with any action or related actions, in addition to any local counsel. The Company shall not be liable for any settlement of any action effected without its written consent (which shall not be unreasonably withheld). In addition, the Company shall not, without the prior written consent of the Placement Agent (which shall not be unreasonably withheld), settle, compromise or consent to the entry of any judgment in or otherwise seek to terminate any pending or threatened action in respect of which indemnification or contribution may be sought hereunder (whether or not such Indemnified Person is a party thereto) unless such settlement, compromise, consent or termination includes an unconditional release of each Indemnified Person from all Liabilities arising out of such action for which indemnification or contribution may be sought hereunder. The indemnification required hereby shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as such expense, loss, damage or liability is incurred and is due and payable.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">14</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(c) In the event that the foregoing indemnity is unavailable to an Indemnified Person other than in accordance with this Agreement, the Company shall contribute to the Liabilities and Expenses paid or payable by such Indemnified Person in such proportion as is appropriate to reflect (i) the relative benefits to the Company, on the one hand, and to the Placement Agent and any other Indemnified Person, on the other hand, of the matters contemplated by this Agreement or (ii) if the allocation provided by the immediately preceding clause is not permitted by applicable law, not only such relative benefits but also the relative fault of the Company, on the one hand, and the Placement Agent and any other Indemnified Person, on the other hand, in connection with the matters as to which such Liabilities or Expenses relate, as well as any other relevant equitable considerations; provided that in no event shall the Company contribute less than the amount necessary to ensure that all Indemnified Persons, in the aggregate, are not liable for any Liabilities and Expenses in excess of the amount of fees actually received by the Placement Agent pursuant to this Agreement. For purposes of this paragraph, the relative benefits to the Company, on the one hand, and to the Placement Agent on the other hand, of the matters contemplated by this Agreement shall be deemed to be in the same proportion as (a) the total value paid or contemplated to be paid to or received or contemplated to be received by the Company in the transaction or transactions that are within the scope of this Agreement, whether or not any such transaction is consummated, bears to (b) the fees paid to the Placement Agent under this Agreement. Notwithstanding the above, no person guilty of fraudulent misrepresentation within the meaning of Section 11(f) of the Securities Act, as amended, shall be entitled to contribution from a party who was not guilty of fraudulent misrepresentation.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(d) The Company also agrees that no Indemnified Person shall have any liability (whether direct or indirect, in contract or tort or otherwise) to the Company for or in connection with advice or services rendered or to be rendered by any Indemnified Person pursuant to this Agreement, the transactions contemplated thereby or any Indemnified Person&#8217;s actions or inactions in connection with any such advice, services or transactions except for Liabilities (and related Expenses) of the Company that are finally judicially determined to have resulted solely from such Indemnified Person&#8217;s gross negligence or willful misconduct in connection with any such advice, actions, inactions or services.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(e) The reimbursement, indemnity and contribution obligations of the Company set forth herein shall apply to any modification of this Agreement and shall remain in full force and effect regardless of any termination of, or the completion of any Indemnified Person&#8217;s services under or in connection with, this Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Section 8. </strong><strong>Representations and Indemnities to Survive Delivery</strong>. The respective indemnities, agreements, representations, warranties and other statements of the Company or any person controlling the Company, of its officers, and of the Placement Agent set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of the Placement Agent, the Company, or any of its or their partners, officers or directors or any controlling person, as the case may be, and will survive delivery of and payment for the Securities sold hereunder and any termination of this Agreement. A successor to a Placement Agent, or to the Company, its directors or officers or any person controlling the Company, shall be entitled to the benefits of the indemnity, contribution and reimbursement agreements contained in this Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">15</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Section 9. </strong><strong>Notices</strong>. All communications hereunder shall be in writing and shall be mailed, hand delivered, e-mailed or telecopied and confirmed to the parties hereto as follows:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If to the Placement Agent to the address set forth above, attention: James Siegal, email: jsiegel@maximgrp.com</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>With a copy to: </em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Ellenoff Grossman &amp; Schole LLP</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">1345 Avenue of the Americas, 11th Floor</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">New York, New York 10105</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">E-mail: mbernstein@egsllp.com</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Attention: Matthew Bernstein</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If to the Company:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Lexaria Bioscience Corp.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">100-740 McCurdy Road, Kelowna</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">British Columbia, Canada VIX 2P7</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">E-mail: cbunka@lexariabioscience.com</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Attention: Chief Executive Officer</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>With a copy to: </em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Sichenzia Ross Ference LLP</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">1185 Avenue of the Americas, 31<sup style="vertical-align:super">st</sup> Floor</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">New York. NY 10036</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">E-mail: gsichenzia@srf.law</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Attention: Gregory Sichenzia</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Any party hereto may change the address for receipt of communications by giving written notice to the others.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">16</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Section 10. </strong><strong>Successors</strong>. This Agreement will inure to the benefit of and be binding upon the parties hereto, and to the benefit of the employees, officers and directors and controlling persons referred to in Section 7 hereof, and to their respective successors, and personal representative, and no other person will have any right or obligation hereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Section 11. </strong><strong>Partial Unenforceability</strong>. The invalidity or unenforceability of any section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other section, paragraph or provision hereof. If any Section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Section 12. </strong><strong>Governing Law. </strong>This Agreement will be governed by, and construed in accordance with, the laws of the State of New York applicable to agreements made and to be performed entirely in such State, without regard to the conflicts of laws principles thereof. This Agreement may not be assigned by either party without the prior written consent of the other party. This Agreement shall be binding upon and inure to the benefit of the parties hereto, and their respective successors and permitted assigns. Any right to trial by jury with respect to any dispute arising under this Agreement or any transaction or conduct in connection herewith is waived. Any dispute arising under this Agreement may be brought into the courts of the State of New York or into the Federal Court located in New York, New York and, by execution and delivery of this Agreement, the Company hereby accepts for itself and in respect of its property, generally and unconditionally, the jurisdiction of aforesaid courts. Each party hereto hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by delivering a copy thereof via overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. The Company agrees that a final judgment in any such action, proceeding or counterclaim brought in any such court shall be conclusive and binding upon the Company and may be enforced in any other courts to the jurisdiction of which the Company is or may be subject, by suit upon such judgment. If either party to this Agreement shall commence an action or proceeding to enforce any provisions of a Transaction Document, then the prevailing party in such action or proceeding shall be reimbursed by the other party for its attorney&#8217;s fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Section 13. </strong><strong>General Provisions</strong>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(a) This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. Notwithstanding anything herein to the contrary, the Engagement Agreement, dated March 13, 2023 (&#8220;<u>Engagement Agreement</u>&#8221;), between the Company and the Placement Agent shall continue to be effective and the terms therein shall continue to survive and be enforceable by the Placement Agent in accordance with its terms, provided that, in the event of a conflict between the terms of the Engagement Agreement and this Agreement, the terms of this Agreement shall prevail. This Agreement may be executed in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit. Section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">(b) The Company acknowledges that in connection with the offering of the Securities: (i) the Placement Agent&#8217;s responsibility to the Company is solely contractual and commercial in nature, (ii) the Placement Agent has acted at arms length, are not agents of, and owe no fiduciary duties to the Company or any other person, (iii) the Placement Agent owes the Company only those duties and obligations set forth in this Agreement and (iv) the Placement Agent may have interests that differ from those of the Company. The Company waives to the fullest extent permitted by applicable law any claims it may have against the Placement Agent arising from a breach or alleged breach of fiduciary duty in connection with the offering of the Securities.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">17</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Section 14. Right of First Refusal.</strong> Upon the Closing of the Placement, for a period of nine (9) months from such Closing the Company grants Maxim the right of first refusal to act as sole managing underwriter and sole book runner, sole placement agent, or sole sales agent, for any and all future public or private equity, equity-linked or debt (excluding commercial bank debt) offerings for which the Company retains the service of an underwriter, agent, advisor, finder or other person or entity in connection with such offering during such nine (9) month period of the Company, or any successor to or any subsidiary of the Company. The Company shall not offer to retain any entity or person in connection with any such offering on terms more favorable than terms on which it offers to retain Maxim. Such offer shall be made in writing in order to be effective. Maxim shall notify the Company within three (3) business days of its receipt of the written offer contemplated above as to whether or not it agrees to accept such retention. If Maxim should decline such retention, the Company shall have no further obligations to Maxim with respect to the offering for which it has offered to retain Maxim, except as otherwise provided for herein.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">[<em>The remainder of this page has been intentionally left blank.</em>]</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">18</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If the foregoing is in accordance with your understanding of our agreement, please sign below whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td>&nbsp;</td> <td colspan="2">Very truly yours,</td> <td></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>LEXARIA BIOSCIENCE CORP.</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">a Nevada corporation</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:47%;">&nbsp;</td> <td style="width:3%;">&nbsp;</td> <td style="width:30%;">&nbsp;</td> <td style="width:15%;">&nbsp;</td></tr> <tr style="height:15px"> <td></td> <td>By:</td> <td style="BORDER-BOTTOM: black 1px solid;">/s Christopher Bunka</td> <td></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td>Name: Christopher Bunka</td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>&nbsp;</td> <td>&nbsp;</td> <td>Title: Chief Executive Officer</td> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The foregoing Placement Agency Agreement is hereby confirmed and accepted as of the date first above written.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td colspan="2"><strong>MAXIM GROUP LLC</strong></td> <td></td></tr> <tr style="height:15px"> <td style="width:3%;">&nbsp;</td> <td style="width:35%;">&nbsp;</td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>By:</td> <td style="BORDER-BOTTOM: black 1px solid;">/s/ Cliff Teller </td> <td></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td>Name: Cliff Teller</td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>&nbsp;</td> <td>Title: Co-President</td> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">19</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>lxrp_ex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html><head><title>lxrp_ex991.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 99.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>KELOWNA, BC</strong> <strong>/ ACCESSWIRE /</strong> <strong>MAY 8, 2023 /</strong> Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the &#8220;Company&#8221; or &#8220;Lexaria&#8221;), a global innovator in drug delivery platforms, today announced the pricing of its public offering of 2,106,000 units, with each unit consisting of one share of common stock and one warrant to purchase one share of common stock. &nbsp;Each unit is being sold at a public offering price of&nbsp;$0.95. The warrants will be immediately exercisable at a price of $0.95 per share and will expire five years from the date of issuance. The shares of common stock and accompanying warrants can only be purchased together in this offering, but will be issued separately and will be immediately separable upon issuance. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Gross proceeds, before deducting placement agent fees and other offering expenses, are expected to be approximately&nbsp;$2.0 million. The offering is expected to close on&nbsp;May 11, 2023, subject to customary closing conditions. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Maxim Group LLC&nbsp;is acting as sole placement agent in connection with this offering.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The securities described above are being offered pursuant to a registration statement on Form S-1, as amended (File No. 333-271096) (the &#8220;Registration Statement&#8221;), which was declared effective by the&nbsp;Securities and Exchange Commission&nbsp;(the &#8220;SEC&#8221;) on&nbsp;May 8, 2023. The offering is being made only by means of a prospectus which is a part of the Registration Statement. A preliminary prospectus relating to the offering has been filed with the&nbsp;SEC. Copies of the final prospectus relating to this offering, when available, will be filed with the&nbsp;SEC&nbsp;and may be obtained from&nbsp;Maxim Group LLC,&nbsp;300 Park Avenue, 16th Floor,&nbsp;New York, NY&nbsp;10022, at (212) 895-3745.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>About Lexaria Bioscience Corp.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Lexaria Bioscience Corp.&#8217;s patented drug delivery technology, DehydraTECH&#8482;, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 30 patents granted and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Forward-Looking Safe Harbor Statement</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as &#8220;anticipate,&#8221; &#8220;if,&#8221; &#8220;believe,&#8221; &#8220;plan,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, the Company&#8217;s ability to satisfy customary closing conditions related to the offering. Such forward-looking statements are estimates reflecting the Company&#8217;s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company&#8217;s ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&amp;D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company&#8217;s public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria&#8217;s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Investor Contact:</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>George Jurcic - Head of Investor Relations</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">ir@lexariabioscience.com</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Phone: 250-765-6424, ext 202</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>lxrp-20230508.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 05/10/2023-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2023 I-NET Business Solutions, Inc. All Rights Reserved.-->
<schema xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:srt="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:lxrp="http://lxrp.com/20230508" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://lxrp.com/20230508">
 <annotation>
  <appinfo>
   <link:roleType roleURI="http://lxrp.com/role/Cover" id="Cover">
    <link:definition>000001 - Document - Cover</link:definition>
    <link:usedOn>link:presentationLink</link:usedOn>
    <link:usedOn>link:calculationLink</link:usedOn>
    <link:usedOn>link:definitionLink</link:usedOn>
   </link:roleType>
   <link:linkbaseRef xlink:type="simple" xlink:href="lxrp-20230508_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
   <link:linkbaseRef xlink:type="simple" xlink:href="lxrp-20230508_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
   <link:linkbaseRef xlink:type="simple" xlink:href="lxrp-20230508_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
   <link:linkbaseRef xlink:type="simple" xlink:href="lxrp-20230508_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
  </appinfo>
 </annotation>
 <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
 <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
 <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
 <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
 <import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
 <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
 <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
 <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
 <import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
 <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
 <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
 <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
 <import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
 <import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
 <import namespace="http://fasb.org/srt-roles/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd" />
 <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
 <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
 <import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
 <import namespace="http://fasb.org/us-roles/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" />
 <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
 <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
 <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>lxrp-20230508_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 05-10-2023-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2023 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address Address Line 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address State Or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address Country</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Security 12b Title</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>lxrp-20230508_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 05-10-2023-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2023 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef  roleURI="http://lxrp.com/role/Cover" xlink:href="lxrp-20230508.xsd#Cover" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://lxrp.com/role/Cover" xlink:title="00000001 - Document - Document and Entity Information" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>lxrp-20230508_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 05-10-2023-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2023 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://lxrp.com/role/Cover" xlink:href="lxrp-20230508.xsd#Cover" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://lxrp.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
    <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>lxrp-20230508_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 05-10-2023-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2023 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef  roleURI="http://lxrp.com/role/Cover" xlink:href="lxrp-20230508.xsd#Cover" xlink:type="simple" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://lxrp.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCover" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140284647719600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 08, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lexaria Bioscience Corp.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001348362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  08,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-2000871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">100-740 McCurdy Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Kelowna<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">BC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address Country</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">V1X 2P7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">765-6424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LEXX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39874<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>lxrp_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lxrp-20230508.xsd" xlink:type="simple"/>
    <context id="From2023-05-08to2023-05-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001348362</identifier>
        </entity>
        <period>
            <startDate>2023-05-08</startDate>
            <endDate>2023-05-08</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-05-08to2023-05-08">0001348362</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-05-08to2023-05-08">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2023-05-08to2023-05-08">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2023-05-08to2023-05-08">2023-05-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2023-05-08to2023-05-08">Lexaria Bioscience Corp.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-05-08to2023-05-08">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2023-05-08to2023-05-08">001-39874</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-05-08to2023-05-08">20-2000871</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-05-08to2023-05-08">100-740 McCurdy Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2023-05-08to2023-05-08">Kelowna</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-05-08to2023-05-08">BC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry contextRef="From2023-05-08to2023-05-08">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="From2023-05-08to2023-05-08">V1X 2P7</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-05-08to2023-05-08">250</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-05-08to2023-05-08">765-6424</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2023-05-08to2023-05-08">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2023-05-08to2023-05-08">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2023-05-08to2023-05-08">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2023-05-08to2023-05-08">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2023-05-08to2023-05-08">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-05-08to2023-05-08">LEXX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-05-08to2023-05-08">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-05-08to2023-05-08">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7>>9
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M)$WS/(X %F>0IA@"IQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04
M"  5BJI6EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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M5!B@?%.9J+SV4VPYZ8Y>9WK_,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04
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MUDX:?^:+X3]>?P%02P$"% ,4    "  5BJI6!T%-8H$   "Q    $
M        @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( !6*JE8I
M;Z3L[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    ( !6*JE:97)PC$ 8  )PG   3              "  <P!
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ %8JJ5I ^&SQ1!
M A$  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;%!+ 0(4 Q0    ( !6*JE:?H!OPL0(  .(,   -              "  90,
M  !X;"]S='EL97,N>&UL4$L! A0#%     @ %8JJ5I>*NQS     $P(   L
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64$L%!@     )  D /@(  .@3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="lxrp_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lxrp.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="lxrp_8k.htm">lxrp_8k.htm</File>
    <File>lxrp-20230508.xsd</File>
    <File>lxrp-20230508_cal.xml</File>
    <File>lxrp-20230508_def.xml</File>
    <File>lxrp-20230508_lab.xml</File>
    <File>lxrp-20230508_pre.xml</File>
    <File>lxrp_ex102.htm</File>
    <File>lxrp_ex991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lxrp_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "calculationLink": {
     "local": [
      "lxrp-20230508_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lxrp-20230508_def.xml"
     ]
    },
    "inline": {
     "local": [
      "lxrp_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lxrp-20230508_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lxrp-20230508_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lxrp-20230508.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "lxrp",
   "nsuri": "http://lxrp.com/20230508",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lxrp_8k.htm",
      "contextRef": "From2023-05-08to2023-05-08",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://lxrp.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lxrp_8k.htm",
      "contextRef": "From2023-05-08to2023-05-08",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line 1"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lxrp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001640334-23-000800-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001640334-23-000800-xbrl.zip
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M2^2FTLQVVKFGV2;A=H:XW];N0+/)](O:_ ,!!M Q!<0J/S*57/[W<Y(;+E3
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M#])A3VY7*N7VSH<XIYM'5_MQ]QM02P,$%     @ %8JJ5EG5_H63 @  1 @
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MIU/VU=QUA%UPGS9%#[5B8.MD8\WK]_ &!W@5$>Y("R/A$4DSTDOCM<TC/SB
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M%<ZTJ)]>F,I/ZF>!Z26<_%3NZG]02P,$%     @ %8JJ5LF@K1:9!   920
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MU^N?LH_^:=V3KW[ZK\VL7S^XF:_,X>C*SJSPU;.31X^?/W[Q-COYY?&+1_^
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M.(#)'<A<V[##3,ZUN!$_0D.(I;JYCW0-]-A\ATDZ]0>HPFDQ+NIL.?[AK+V
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M#K[H.<1:FS#LP[,G>XD(P)0.]=7[#*[1<*9%1(Q5JS^'&DP 3^+R'P)AKL7
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MV%V%6W_05_\J:?_I) Z6Q:JJ+^_'9[$JNM.JN7^$P_]1LDMG@CVFZ/1\-P(
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M,.U+#^$OG>M[FTW._;4U$K*#!PVUB;&KE1!%2?J[4G;_W3=P\F7SKZK(7K=
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MW375(HF2= NKPO;E,-3>1/6?Y1P)B2"@Y8&^'Q0; T%I4A@2RZ@(9,]^ !O
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M[:FXH@2^; "QE020K8#P")O9>EM*8(K3$UYU,E/U^VY# LB3[WLN6VR=]_[
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MT$$P8'%L*@+"D:@6J#(XB.H/S1T/N0@YETY;3U5I0M8X+ZUG!ZU]OHJ[*0I
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M     &QX<G M,C R,S U,#@N>'-D4$L! A0#%     @ %8JJ5G)(&@G9 0
MBP,  !4              ( !M@0  &QX<G M,C R,S U,#A?8V%L+GAM;%!+
M 0(4 Q0    ( !6*JE99U?Z%DP(  $0(   5              "  <(&  !L
M>')P+3(P,C,P-3 X7V1E9BYX;6Q02P$"% ,4    "  5BJI6$#G6IRL&  "#
M.0  %0              @ &("0  ;'AR<"TR,#(S,#4P.%]L86(N>&UL4$L!
M A0#%     @ %8JJ5LF@K1:9!   920  !4              ( !Y@\  &QX
M<G M,C R,S U,#A?<')E+GAM;%!+ 0(4 Q0    ( !6*JE;'=UY"N14  )B,
M   +              "  ;(4  !L>')P7SAK+FAT;5!+ 0(4 Q0    ( !6*
MJE;<95C'9%0  +BS 0 .              "  90J  !L>')P7V5X,3 R+FAT
M;5!+ 0(4 Q0    ( !6*JE;#,G/VZPL  /<E   .              "  21_
F  !L>')P7V5X.3DQ+FAT;5!+!08     "  ( /P!   [BP     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
